The Worldwide Market for Liquid Biopsy (by Analyte [ctDNA, cfDNA, Other], by Application - Screening/Drug Monitoring/Diagnostic, by Region [US, Europe, Asia, ROW] and by Type of Cancer)

Jul 7, 2017
210 Pages - Pub ID: KLI15405872
Share this report
 
Online Download $4,200
Departmental Site License (one location, up to 10 users) $5,500
Global Site License $8,400

The Worldwide Market for Liquid Biopsy



The term liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

The Worldwide Market for Liquid Biopsy contains markets for the following:

  • Liquid Biopsy Technology Market Size and Forecast (CTC / ctDNA, cfDNA, EV and Other) 
  • Liquid Biopsy Application Market Size and Forecast (Screening, Therapy, Drug Monitoring) 
  • Liquid Biopsy Analyte Type Market Size and Forecast (Cancer, Infectious Disease, Other) 
  • Liquid Biopsy Geographic Market (US, EU, Asia, ROW) 
  • Top Ten Companies 
  • Market and Technology Overview
  • Trends in the Market
  • Profiles of Liquid Biopsy Competitors 

Liquid Biopsy Testing Applications in Oncology include:


  • Early diagnosis of cancer/ Screening
  • Therapy personalization and monitoring – to help the physician select optimal therapies for individual patients and monitor their efficacy, as well as explore other options of treatment when the patient becomes resistant to current therapies
  • Disease monitoring – to monitor residual disease, disease progression and tumor evolution, and detect recurrence earlier
  • Prognosis of disease evolution
  • Alternative method of testing when tissue samples are difficult/impossible to obtain, or when the primary site of metastatic disease is unknown.

Liquid Biopsy Technologies


The currently available liquid biopsy technologies employ the analysis of various types of analytes, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, proteins, miRNA and mRNA. Among them, ctDNA and CTCs have been the most explored technologies for commercial applications up to the present time.

  • Circulating tumor DNA (ctDNA) encompasses the small fragments of DNA that are believed to originate from the natural and abnormal necrosis and apoptosis processes that tumor cells undergo regularly. ctDNA fragments have the advantage of being available from different types of specimens, including urine, plasma, blood, and cerebrospinal fluid, but are rare and have a short half-life in the bloodstream, which makes their isolation and identification highly challenging. Since many cancer patients shed only very small DNA fragments into the bloodstream, ctDNA-based diagnostic technologies need to be highly sensitive in order to detect such rare events. Furthermore, ctDNA cannot provide information about protein expression, and the analysis of RNA is also difficult and limited using ctDNA. ctDNA may also result from tumor cells killed by therapeutic drugs, and does not capture information about the residual cancer that may not respond to the particular therapy or has become resistant to it. 
  • Circulating tumor cells (CTCs) are cancer cells that are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs, initiating the process of metastasis, and forming new tumors. Similarly to ctDNA, CTC-based tests could offer significant advantages compared to tissue biopsies, as they may be able to capture the heterogeneity of tumors and their genetic evolution during the disease progression and therapy. Compared to ctDNA, CTCs have a longer half-life in blood, and the analysis of viable cells could provide information about protein expression, such as PD-L1 or ER, which is not possible with ctDNA. Also, since CTCs contain intact genomic material from tumors, their analysis can reveal additional information about the biology of cancer and metastasis that is not possible to obtain from ctDNA. 
  • Exosomes are nanometer-sized extracellular membrane vesicles secreted by cells in the extracellular environment on a continuous basis. Exosomes circulate in great abundance and are highly stable in all biological fluids, and contain molecular information from their parental cells, included in proteins and various nucleic acids. Moreover, exosomes are involved in many cellular processes and carry information about tumor growth, metastasis, and drug resistance, which is not available from the analysis of circulating free DNA. Despite their advantages, the analysis of exosomes for diagnostic purposes poses various challenges that complicate considerably their use in the development of commercial diagnostics. Due to the complex composition of biological fluids, the detection and isolation of high purity exosomes is a long process that imposes the use of multiple techniques based on various parameters. 

Liquid Biopsy Competitor Profiles:

 
CTCs 
  • Biocept 
  • Cynvenio Biosystems  
  • Epic Sciences  
  • GILUPI  
  • Menarini-Silicon Biosystems  
  • Qiagen  
  • Angle  
  • Biocept  
  • Epic Sciences  
  • Janssen Diagnostics 
Extracellular Vesicles
  • Biodesix
  • Exosome Diagnostics
  • Gensignia
  • Hologic
cfDNA
  • Adaptive Biotechnologies  
  • Biodesix  
  • Epigenomics  
  • Foundation Medicine  
  • Genomic Health  
  • Guardant Health  
  • Myriad Genetics  
  • Pathway Genomics  
  • Personal Genome Diagnostics  
  • Qiagen 
  • Roche Diagnostics  
  • Sysmex-Inostics  
  • Trovagene
  • Adaptive Biotechnologies  
  • Biocartis  
  • Epigenomics  
  • Exact Sciences  
  • Foundation Medicine  
  • Genomic Health  
  • GRAIL  
  • Inivata  
  • Natera  

CHAPTER ONE: EXECUTIVE SUMMARY
INTRODUCTION
LIQUID BIOPSY TECHNOLOGIES
INDUSTRY STRUCTURE
LIQUID BIOPSY MARKET REVENUES AND FORECAST
Figure 1-1 Global Liquid BiopsyMarketEstimated Breakdown by Geographic Region, 2016
Figure 1-2 Global Liquid Biopsy Market Forecastby Geographic Region ($ millions), 2015-2021
CHAPTER TWO: LIQUID BIOPSY TECHNOLOGIES
INTRODUCTION
CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
CHAPTER THREE: CIRCULATING TUMOR DNA (CFDNA) LIQUID BIOPSY
INTRODUCTION
ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
Adaptive Biotechnologies
Biodesix
Epigenomics
Foundation Medicine
Genomic Health
Guardant Health
Myriad Genetics
Pathway Genomics
Personal Genome Diagnostics
QIAGEN
Roche Diagnostics
Sysmex-Inostics
Trovagene
CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
Adaptive Biotechnologies
Biocartis
The Worldwide Market for Liquid Biopsy
ii July 2017© Kalorama Information
Epigenomics
Exact Sciences
Foundation Medicine
Genomic Health
GRAIL
Inivata
Natera
Trovagene
CHAPTER FOUR: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY
INTRODUCTION
CHALLENGES IN THE DEVELOPMENT OF CTCS-BASED LIQUID BIOPSY TESTS
CTCS-BASED LIQUID BIOPSY TESTS
Biocept
Cynvenio Biosystems
Epic Sciences
GILUPI
Menarini-Silicon Biosystems
QIAGEN
CTCS-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
Angle
Biocept
Epic Sciences
Janssen Diagnostics
CHAPTER FIVE: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY
INTRODUCTION
LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES
Biodesix
Exosome Diagnostics
Gensignia
Hologic
MDxHealth
OncoCyte
QIAGEN
Vermillion
VolitionRx
CHAPTER SIX: LIQUID BIOPSY INDUSTRY ANALYSIS
INTRODUCTION
TIERS OF COMPETITION
COMPETITIVE FACTORS
SIGNIFICANT MARKET TRENDS
CHAPTER SEVEN: LIQUID BIOPSY MARKET SIZE AND FORECAST
MARKET SNAPSHOT
Figure 7-1 Global Liquid Biopsy Diagnostics Market Estimated Breakdown by Type of Analyte, 2016
Figure 7-2 Global Liquid Biopsy Diagnostics Market Estimated Breakdown by Geographic Region, 2016
MARKET FORECAST
Figure 7-3 Global Liquid BiopsyMarketForecastby Geographic Region ($ millions), 2015-2021
CHAPTER EIGHT: MARKET BY TYPE OF ANALYTE
CIRCULATING TUMOR DNA
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Analyte ($ millions), 2015-2021
CIRCULATING TUMOR CELLS
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Analyte ($ millions), 2015-2021
EXTRACELLULAR VESICLES/ OTHER ANALYTES
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Analyte ($ millions), 2015-2021
CHAPTER NINE: MARKET BY TYPE OF APPLICATION
THERAPY GUIDANCE AND MONITORING
Market Snapshot
Revenue Forecast
Figure 9-1 Global Liquid Biopsy Market by Type of Application ($ millions), 2015-2021
DIAGNOSIS/ SCREENING
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Application ($ millions), 2015-2021
DISEASE PROGNOSIS
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Application ($ millions), 2015-2021
CHAPTER TEN: MARKET BY TYPE OF CANCER
BREAST CANCER
Market Snapshot
Revenue Forecast
Figure 10-1 Global Liquid Biopsy Market by Type of Cancer ($ millions), 2015-2021
COLORECTAL CANCER
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
LUNG CANCER
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
OVARIAN CANCER
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
PROSTATE CANCER
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
OTHER CANCERS
Market Snapshot
Revenue Forecast
Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
CHAPTER ELEVEN: LIQUID BIOPSY COMPANY PROFILES
TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
BIOCEPT, INC.
EPIGENOMICS
FOUNDATION MEDICINE, INC.
GENOMIC HEALTH
GUARDANT HEALTH, INC.
MENARINI-SILICON BIOSYSTEMS
MYRIAD GENETICS, INC.
NEOGENOMICS
QIAGEN N.V.
ROCHE DIAGNOSTICS
OTHER COMPANIES ACTIVATING IN THE LIQUID BIOPSY MARKET
ADAPTIVE BIOTECHNOLOGIES
ANGLE, PLC
BIOCARTIS
BIODESIX
CYNVENIO BIOSYSTEMS
EPIC SCIENCES
EXACT SCIENCES
EXOSOME DIAGNOSTICS, INC.
GENSIGNIA
GILUPI GMBH
GRAIL
HOLOGIC, INC.
INIVATA
MDXHEALTH
NATERA
ONCOCYTE
PATHWAY GENOMICS
PERSONAL GENOME DIAGNOSTICS
RESOLUTION BIOSCIENCES
ROSETTA GENOMICS
SYSMEX-INOSTICS, INC.
TROVAGENE, INC.
VERMILLION, INC.
VOLITIONRX

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.